IRCT20200509047364N2
Recruiting
Phase 3
The effect of Famotidine on the improvement of patients with COVID-19
Bandare-abbas University of Medical Sciences0 sites20 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- aboratory confirmed COVID-19.
- Sponsor
- Bandare-abbas University of Medical Sciences
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All COVID\-19 patients whose disease has been confirmed by the PCR test for SARS\-Cov\-2\.
- •Signing the written consent of the study participant.
Exclusion Criteria
- •All Immunocompromised patients
- •End stage renal disease
- •Moderate renal insufficiency (creatinine clearance 30\-50 mL/min)
- •stage 4 sever chronic kidney disease
- •requiring dialysis (i.e creatinine clearance \<30 mL/min)
- •History of hepatic disease
- •History of hepatitis C infection
- •History of alcoholism
- •G\-6\-PD (glucose\-6\-phosphate dehydrogenase deficiency)
- •ALT/AST \>5 times the upper limit of normal.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The effect of famotidine on reducing the side effects of prostate cancer radiotherapyIRCT20231121060132N1Kermanshah University of Medical Sciences50
Recruiting
Not Applicable
Bioequivalence study of Famotidine SuspensioIn the present study, the products will be administered to healthy volunteers.IRCT20210519051345N44Tabriz University of Medical Sciences24
Active, not recruiting
Phase 1
FAMODREP : Interest of Famotidine in Reducing Endothelial Expression of P-selectin in Children With Sickle Cell Disease: Pilot Study, Single-center, Prospective, Non-comparativeSickle Cell DiseaseTherapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]CTIS2022-502144-12-00Assistance Publique Hopitaux De Paris30
Not yet recruiting
Phase 2
Famotidine for the improvement of cognitive impairments in COVID-19 patientsCOVID-19.COVID-19, virus identifiedU07.1IRCT20090117001556N138Tehran University of Medical Sciences50
Completed
Phase 1
Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy- induced Acute Toxicity in Patients with Prostate CancerProstate CancerBowel toxicityUrinary toxicityCancer - ProstateOral and Gastrointestinal - Normal oral and gastrointestinal development and functionRenal and Urogenital - Normal development and function of male and female renal and urogenital systemACTRN12612000101886School of Paramedical Sciences, Shahid Beheshti Medical University,36